• Jiacheng Yu, Bailing Hou, Yulin Huang, Xiaoyu Wang, Yue Qian, Ying Liang, Xiaoping Gu, Zhengliang Ma, and Yue Sun.
• Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China.
• Eur J Pain. 2023 Jul 1; 27 (6): 723734723-734.

BackgroundUbiquitin-mediated degradation of the Mas-related G protein-coupled receptor C (MrgC) reduces the number of receptors. However, the specific deubiquitinating enzyme antagonize this process has not been reported. In this study, we investigated the effect of ubiquitin-specific protease-48 (USP48) on bone cancer pain (BCP) and its effect on MrgC.MethodsA mouse model of BCP was established. BCP behaviours of mice were assessed after intrathecal injection of adeno-associated virus (AAV)-USP48. USP48 and MrgC interactions were studied by immunoprecipitation. Overexpression and knockdown of USP48 were conducted in N2a cells to investigate the effect of USP48 on MrgC receptor number and ubiquitination.ResultsSpinal cord level USP48 expression was reduced in mice with BCP. Intrathecal injection of AAV-USP48 increased paw withdrawal mechanical threshold and reduced spontaneous flinching in mice. In N2a cells, there were increased number of MrgC receptors after overexpression of USP48 and decreased number of MrgC receptors after knockdown of USP48. USP48 interacted with MrgC and overexpression of USP48 altered the level of ubiquitination of MrgC.ConclusionUSP48 antagonizes ubiquitin-mediated autophagic degradation of MrgC and alleviates BCP in a murine animal model. Our findings may provide a new perspective for the treatment of BCP.SignificanceOur finding may provide an important theoretical basis as well as an intervention target for clinical development of drugs for BCP.© 2023 European Pain Federation - EFIC ®.

29 keywords...

hide…